CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2002 | 4 | 1 | 5 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 3 | 5 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 3 | 7 |
| 2011 | 5 | 2 | 7 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 4 | 1 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 5 | 2 | 7 |
| 2020 | 1 | 4 | 5 |
| 2021 | 2 | 3 | 5 |
| 2022 | 3 | 1 | 4 |
| 2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Ancestry-based differences in the immune phenotype are associated with lupus activity. JCI Insight. 2023 08 22; 8(16).
-
Progressive cognitive impairment after recovery from neuroinvasive and non-neuroinvasive Listeria monocytogenes infection. Front Immunol. 2023; 14:1146690.
-
Osteopontin contributes to virus resistance associated with type I IFN expression, activation of downstream ifn-inducible effector genes, and CCR2+CD115+CD206+ macrophage infiltration following ocular HSV-1 infection of mice. Front Immunol. 2022; 13:1028341.
-
Localized ablative immunotherapy drives de novo CD8+ T-cell responses to poorly immunogenic tumors. J Immunother Cancer. 2022 Oct; 10(10).
-
?c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1. Cytotherapy. 2022 Dec; 24(12):1232-1244.
-
Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clin Transl Med. 2022 07; 12(7):e937.
-
The timing of differentiation and potency of CD8 effector function is set by RNA binding proteins. Nat Commun. 2022 04 27; 13(1):2274.
-
Noncognate Signals Drive Enhanced Effector CD8+ T Cell Responses through an IFNAR1-Dependent Pathway after Infection with the Prototypic Vaccine, 0?NLS, against Herpes Simplex Virus 1. J Virol. 2022 03 23; 96(6):e0172421.
-
Combined Deficiency of the Melanocortin 5 Receptor and Adenosine 2A Receptor Unexpectedly Provides Resistance to Autoimmune Disease in a CD8+ T Cell-Dependent Manner. Front Immunol. 2021; 12:742154.
-
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell. 2021 11 08; 39(11):1497-1518.e11.